$DARE
Dare Bioscience, Inc.

2018 Q2 Form 10-Q Financial Statement

#000156459018021487 Filed on August 13, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2017 Q2
Revenue $0.00 $642.0K
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.410M $480.0K
YoY Change 193.75% -117.45%
% of Gross Profit
Research & Development $2.218M $0.00
YoY Change -100.0%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $3.625M $480.0K
YoY Change 655.17% -95.34%
Operating Profit -$3.625M -$479.6K
YoY Change 655.76%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $42.63K -$18.57K
YoY Change -329.54% -96.71%
Pretax Income -$3.580M -$500.0K
YoY Change 616.0% -103.82%
Income Tax
% Of Pretax Income
Net Earnings -$3.582M -$500.0K
YoY Change 616.43% -95.4%
Net Earnings / Revenue -77.88%
Basic Earnings Per Share
Diluted Earnings Per Share -$313.5K -$549.5K
COMMON SHARES
Basic Shares Outstanding 11.42M 910.0K
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.45M $7.240M
YoY Change 71.96% -84.66%
Cash & Equivalents $12.45M $39.41K
Short-Term Investments
Other Short-Term Assets $350.0K
YoY Change
Inventory
Prepaid Expenses
Receivables $890.0K
Other Receivables $0.00
Total Short-Term Assets $12.82M $8.130M
YoY Change 57.69% -83.38%
LONG-TERM ASSETS
Property, Plant & Equipment $7.910K $20.00K
YoY Change -60.45% -97.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $660.0K $0.00
YoY Change -100.0%
Total Long-Term Assets $660.0K $21.00K
YoY Change 3042.86% -97.84%
TOTAL ASSETS
Total Short-Term Assets $12.82M $8.130M
Total Long-Term Assets $660.0K $21.00K
Total Assets $13.48M $8.151M
YoY Change 65.38% -83.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.270M $660.0K
YoY Change 92.42% -58.49%
Accrued Expenses $189.0K
YoY Change -96.1%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $1.270M $3.350M
YoY Change -62.09% -76.84%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $0.00 $740.0K
YoY Change -100.0% -21.36%
Total Long-Term Liabilities $0.00 $740.0K
YoY Change -100.0% -92.28%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.270M $3.350M
Total Long-Term Liabilities $0.00 $740.0K
Total Liabilities $1.270M $4.090M
YoY Change -68.95% -83.0%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.22M $4.060M
YoY Change
Total Liabilities & Shareholders Equity $13.48M $8.150M
YoY Change 65.4% -83.66%

Cashflow Statement

Concept 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$3.582M -$500.0K
YoY Change 616.43% -95.4%
Depreciation, Depletion And Amortization $0.00 $0.00
YoY Change -100.0%
Cash From Operating Activities -$2.690M -$110.0K
YoY Change 2345.45% -99.02%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$450.0K $0.00
YoY Change
Cash From Investing Activities -$460.0K $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 60.00K
YoY Change -100.0% -103.05%
NET CHANGE
Cash From Operating Activities -2.690M -110.0K
Cash From Investing Activities -460.0K 0.000
Cash From Financing Activities 0.000 60.00K
Net Change In Cash -3.150M -50.00K
YoY Change 6200.0% -99.62%
FREE CASH FLOW
Cash From Operating Activities -$2.690M -$110.0K
Capital Expenditures -$10.00K $0.00
Free Cash Flow -$2.680M -$110.0K
YoY Change 2336.36% -99.01%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7910
CY2017Q4 us-gaap Goodwill
Goodwill
5187519
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
392
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
5187519
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3624796
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-479623
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
42626
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-18570
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-3582170
dare License Fee
LicenseFee
350000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2460363
CY2018Q2 dare License Fee
LicenseFee
250000
CY2018Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-27485
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-460200
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-41231
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3609655
CY2017Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-498193
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11289018
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-742057
CY2018Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11422161
CY2017Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
910000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10031249
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
910000
us-gaap Profit Loss
ProfitLoss
-11247787
us-gaap Profit Loss
ProfitLoss
-742057
us-gaap Depreciation
Depreciation
288
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
452000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-259562
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
35838
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-193495
dare Increase Decrease In Other Assets And Deferred Charges
IncreaseDecreaseInOtherAssetsAndDeferredCharges
-66160
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
298585
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
550666
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
33976
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-75
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-2800
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4807544
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-160209
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
452000
dare Net Proceeds From Issuance Of Common Stock And Warrants
NetProceedsFromIssuanceOfCommonStockAndWarrants
10195653
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
155000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10195653
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
155000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-41231
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4886678
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5209
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44614
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39405
dare Number Of Common Stock Warrants Exercised
NumberOfCommonStockWarrantsExercised
0
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of stock-based compensation, goodwill impairment and purchase accounting. Actual results could differ from those estimates and could materially affect the reported amounts of assets, liabilities and future operating results.</p></div>
CY2018Q2 dare Number Of Clinical Stage Assets Assembled As Portfolio
NumberOfClinicalStageAssetsAssembledAsPortfolio
2
CY2018Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5000000
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-10
CY2017Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2018Q1 dare Stock Purchase Transaction Completion Date
StockPurchaseTransactionCompletionDate
2017-07-19
CY2018Q1 dare Stock Option Modification Approval Date
StockOptionModificationApprovalDate
2017-03-19
CY2017 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
7500000
CY2017Q3 us-gaap Goodwill
Goodwill
12700000
CY2018Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
5200000
CY2018Q2 us-gaap Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
35123
dare Weighted Average Amortization Period
WeightedAverageAmortizationPeriod
P2Y3M29D
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
539896
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
7675
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
529721
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
31.40
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.68
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
30.98
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
31.89
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0276
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.24
dare Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.61
CY2018Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5000000
CY2018Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.70
CY2018Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.00
CY2018Q1 dare Gross Proceeds From Offering Of Common Stock And Warrants
GrossProceedsFromOfferingOfCommonStockAndWarrants
10300000
CY2018Q1 dare Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
9400000
CY2018Q1 dare Class Of Warrant Or Right Expiration Period
ClassOfWarrantOrRightExpirationPeriod
P5Y
dare Number Of Common Stock Warrants Exercised
NumberOfCommonStockWarrantsExercised
0
CY2018Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3751002
CY2018Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4298573
CY2017Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10519
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4298573
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10519

Files In Submission

Name View Source Status
0001564590-18-021487-index-headers.html Edgar Link pending
0001564590-18-021487-index.html Edgar Link pending
0001564590-18-021487.txt Edgar Link pending
0001564590-18-021487-xbrl.zip Edgar Link pending
dare-10q_20180630.htm Edgar Link pending
dare-20180630.xml Edgar Link completed
dare-20180630.xsd Edgar Link pending
dare-20180630_cal.xml Edgar Link unprocessable
dare-20180630_def.xml Edgar Link unprocessable
dare-20180630_lab.xml Edgar Link unprocessable
dare-20180630_pre.xml Edgar Link unprocessable
dare-ex1010_233.htm Edgar Link pending
dare-ex101_230.htm Edgar Link pending
dare-ex102_231.htm Edgar Link pending
dare-ex103_157.htm Edgar Link pending
dare-ex104_158.htm Edgar Link pending
dare-ex105_237.htm Edgar Link pending
dare-ex106_236.htm Edgar Link pending
dare-ex107_234.htm Edgar Link pending
dare-ex108_235.htm Edgar Link pending
dare-ex109_232.htm Edgar Link pending
dare-ex311_6.htm Edgar Link pending
dare-ex312_9.htm Edgar Link pending
dare-ex31_181.htm Edgar Link pending
dare-ex321_8.htm Edgar Link pending
dare-ex322_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g2vmzlqnmruv000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending